These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3283950)

  • 1. [Use of aminoglutethimide (orimeten) in advanced breast cancer].
    Garin AM; Nadezhdina TM; Lichinitser MR; Pokryshkin VI
    Sov Med; 1988; (1):31-4. PubMed ID: 3283950
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of aminoglutethimide (orimeten) in disseminated breast cancer].
    Nadezhdina TM; Vyshinskaia GV; Lichinitser MR; Bassalyk LS; Garin AM
    Vopr Onkol; 1987; 33(5):79-82. PubMed ID: 3590672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer.
    Powles TJ; Coombes RC; Smith IE; Chilvers C; Easton D; Thomas L; Adcock H; Gazet JC; Nash AG; Bradbeer J
    Breast Cancer Res Treat; 1986; 7 Suppl():S37-40. PubMed ID: 3527305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast].
    Bonneterre J; Pion JM; Demaille A
    Bull Cancer; 1987; 74(3):241-7. PubMed ID: 3304478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early results of hormonal treatment of advanced breast cancer with aminoglutethimide].
    Pieńkowski T; Zborzil J; Siedlecki P; Flis E; Pałucka A; Pieńkowska F; Rubách M; Piotrowski J
    Pol Tyg Lek; 1988 Aug; 43(33):1057-9. PubMed ID: 3072540
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic factors affecting response to aminoglutethimide in advanced breast cancer.
    Brufman G
    Anticancer Res; 1993; 13(4):1235-7. PubMed ID: 8352549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Remission of cutaneous metastases of breast therapy cancer during aminoglutethimide (Orimeten)].
    Josephsen PG; Pedersen C
    Ugeskr Laeger; 1983 Jul; 145(28):2156-7. PubMed ID: 6612854
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer.
    Coombes RC; Powles TJ; Easton D; Chilvers C; Ford HT; Smith IE; McKinna A; White H; Bradbeer J; Yarnold J
    Cancer Res; 1987 May; 47(9):2494-7. PubMed ID: 3552216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Postoperative hormone therapy of breast cancer (analysis of overall survival)].
    Semiglazov VF; Ivanov VG; Ivanova OA; Moiseenko VM; Tsyrlina EV; Barash NI; Popova RT; Migmanova NS; Seleznev IK; Bozhok AA
    Vopr Onkol; 1996; 42(6):37-42. PubMed ID: 9123900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
    Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
    Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials referral resource. Advanced breast cancer.
    Cheson BD
    Oncology (Williston Park); 1989 Jul; 3(7):113-4, 121-3. PubMed ID: 2641908
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
    Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
    Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of the preparation Orimeten in the treatment of advanced cases of breast cancer in women].
    Bassara H; Ramlau C
    Nowotwory; 1987; 37(2):148-53. PubMed ID: 3313288
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast.
    Wells SA; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H; White D; Smart E; Cox C; Santen RJ
    Cancer Res; 1982 Aug; 42(8 Suppl):3454s-3457s. PubMed ID: 7044527
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of advanced breast cancer with aminoglutethimide].
    Lønning PE; Kvinnsland S
    Tidsskr Nor Laegeforen; 1984 Nov; 104(31):2185-7. PubMed ID: 6531774
    [No Abstract]   [Full Text] [Related]  

  • 17. Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
    Höffken K; Kempf H; Miller AA; Miller B; Schmidt CG; Faber P; Kley HK
    Cancer Treat Rep; 1986 Oct; 70(10):1153-7. PubMed ID: 3756937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoglutethimide in the management of advanced breast cancer.
    Smith IE; Coombes RC; Ford HT; Gazet JC; Harmer C; Jones M; McKinna JA; Powles TJ
    Eur J Cancer (1965); 1980; Suppl 1():99-101. PubMed ID: 7318876
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of metastatic breast cancer with aminoglutethimide after failure of tamoxifen].
    Brufman G; Biran S
    Harefuah; 1984 Dec; 107(12):377-99. PubMed ID: 6532917
    [No Abstract]   [Full Text] [Related]  

  • 20. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
    Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ
    Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.